Migration instrument specifies income threshold and salary rate

The Australian Department of Home Affairs has issued a legislative instrument specifying the income threshold and annual earnings, along with the methodology for determining the annual market salary rate for migration purposes. This instrument amends the Migration Regulations 1994 and impacts employers sponsoring foreign workers.

Migration Legislation Amendment (Assessing Authorities) Instrument 2026

The Australian Department of Home Affairs has issued the Migration Legislation Amendment (Assessing Authorities) Instrument 2026, which amends existing instruments related to skilled migration visas. This instrument specifies occupations and relevant assessing authorities for various visa subclasses, impacting the eligibility and application processes for skilled workers seeking to migrate to Australia.

My Health Records Regulations 2026 Now In Force

The My Health Records Regulations 2026 have come into force in Australia, administered by the Department of Health, Disability and Ageing. These regulations are authorised by the My Health Records Act 2012 and establish rules for the My Health Records system, including registration and data handling.

Interest Rate for Defence-Related Claims Compensation

The Australian Department of Veterans' Affairs has issued a new instrument establishing the interest rate for defence-related claims compensation. This rule, effective March 27, 2026, is authorized by the Safety, Rehabilitation and Compensation (Defence-related Claims) Act 1988.

Woomera Prohibited Area Exclusion Periods Determination 2026

The Australian Department of Defence has issued a determination setting exclusion periods for Amber Zones 1 and 2 within the Woomera Prohibited Area for the period of July 1, 2026, to December 31, 2026. This determination is authorized under the Woomera Prohibited Area Rule 2014.

Patent Application: Cancer Treatment with Stat3 Decoy

The USPTO has published a new patent application (US20260085318A1) detailing methods for treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor. The application was filed on September 20, 2023, by inventors Daniel E. Johnson and Jennifer R. Grandis.

siRNA for AGT gene expression inhibition in hypertension treatment

The USPTO has published a new patent application (US20260085317A1) detailing modified oligonucleotide sequences designed as siRNAs to inhibit angiotensinogen (AGT) gene expression. The application suggests these siRNAs may be used in the development of treatments for hypertension and related diseases.

HMBOX1 Inhibitor for Muscle Atrophy Treatment

The USPTO has published a patent application (US20260085316A1) from Shanghai University detailing the use of a homeobox containing 1 (HMBOX1) inhibitor for the prevention and treatment of muscle atrophy. The application outlines findings from cellular and animal studies supporting the therapeutic potential of inhibiting HMBOX1 expression.

Engineered Polynucleotide for Cancer Treatment

The USPTO has published a patent application detailing an engineered polynucleotide designed to treat cancer by regulating gene expression. The application, filed on July 17, 2025, describes compositions and methods involving polynucleotides that interact with pre-mRNA and spliceosomes.

Conjugated Oligonucleotide Compounds for Therapeutic Use

The USPTO has published a new patent application (US20260085314A1) for conjugated oligonucleotide compounds, methods of making them, and their therapeutic uses. The application was filed on May 16, 2025, by inventors Ahmad Ali Mortazavi, Viviana Mannella, and Muthusamy Jayaraman.